tradingkey.logo
tradingkey.logo
Search

Virax Biolabs Group Ltd

VRAX
Add to Watchlist
0.153USD
+0.013+9.64%
Close 05/15, 16:00ETQuotes delayed by 15 min
3.06MMarket Cap
LossP/E TTM

Virax Biolabs Group Ltd

0.153
+0.013+9.64%

More Details of Virax Biolabs Group Ltd Company

Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Virax Biolabs Group Ltd Info

Ticker SymbolVRAX
Company nameVirax Biolabs Group Ltd
IPO dateJul 14, 2022
CEOFoster (James)
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 14
AddressBiocity Glasgow
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeML1 5UH
Phone4402077887414
Websitehttps://www.viraxbiolabs.com
Ticker SymbolVRAX
IPO dateJul 14, 2022
CEOFoster (James)

Company Executives of Virax Biolabs Group Ltd

Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Principal Accounting Officer, Co-Founder
287.99K
--
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Wed, Feb 25
Updated: Wed, Feb 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
4.14%
Foster (James)
1.45%
Mccracken (Nigel Ph.D.)
0.12%
XTX Markets LLC
0.11%
Norton (Evan)
0.08%
Other
94.12%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
4.14%
Foster (James)
1.45%
Mccracken (Nigel Ph.D.)
0.12%
XTX Markets LLC
0.11%
Norton (Evan)
0.08%
Other
94.12%
Shareholder Types
Shareholders
Proportion
Hedge Fund
4.14%
Individual Investor
1.79%
Venture Capital
0.11%
Bank and Trust
0.03%
Other
93.93%

Institutional Shareholding

Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
22
851.39K
4.27%
+268.60K
2025Q4
21
327.00K
4.41%
+50.97K
2025Q3
22
263.22K
6.06%
-53.31K
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
823.91K
9.21%
+595.87K
+261.30%
Dec 31, 2025
Foster (James)
287.99K
3.22%
--
--
Mar 31, 2025
Mccracken (Nigel Ph.D.)
23.33K
0.26%
+23.33K
--
Mar 31, 2025
XTX Markets LLC
21.44K
0.24%
+21.44K
--
Dec 31, 2025
Norton (Evan)
15.33K
0.17%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.17%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.17%
+15.33K
--
Mar 31, 2025
National Bank of Canada
6.00K
0.07%
-4.00K
-40.00%
Dec 31, 2025
Farther Finance Advisors, LLC
21.00
0%
--
--
Dec 31, 2025
Osaic Holdings, Inc.
20.00
0%
+20.00
--
Dec 31, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
Dec 14, 2023
Merger
10→1
KeyAI